Chronic Hepatitis B Virus Infection Pipeline Market Research Report 2022: Comprehensive Insights About 40+ Companies and 40+ Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Chronic Hepatitis B Virus Infection Emerging Drugs Chapters

This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Hepatitis B Virus Infection Emerging Drugs

HS-10234: Jiangsu Hansoh Pharmaceutical

HS 10234, an oral nucleoside reverse transcriptase inhibitor (nucleoside analog) is being developed by Hansoh Pharma, for the treatment of chronic hepatitis B. HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. It is currently being investigated in Phase III stage of development.

DA 2802: Dong-A ST

Tenofovir disoproxil orotate designated as DA 2802 is an oral small molecule being developed by Dong-A ST for the treatment of viral infections. A Phase III Clinical Trial Evaluating the Antiviral Activity and Safety of DA-2802(Tenofovir Disoproxil Orotate) and Viread(Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients has been completed.

VIR-2218: Vir Biotechnology

VIR-2218, an HBV-targeting siRNA, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is hypothesized to remove the inhibition of T cell activity directed against HBV. It is believed that achieving a functional cure for many HBV patients may be enabled by using VIR-2218 in combination with other agents. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B virus infection.

AB-729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient's immune system to respond to the virus. AB-729 targets hepatocytes using our novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology.

AB-729 is currently being evaluated in a Phase IIa randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFN?-2a in 40 patients with chronic HBV infection. The primary objective of the clinical trial is to evaluate the safety and tolerability of AB-729 plus Peg-IFN?-2a in subjects with NA-suppressed chronic HBV infection. AB-729 is also being evaluated in several additional phase IIa studies with outside partners in clinical collaborations.

Major Players in Chronic Hepatitis B Virus Infection

There are approx. 40+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the mid to advanced stage, i.e. phase III include, Jiangsu Hansoh Pharmaceutical

Route of AdministrationChroni

Key Players

• Gilead Sciences
• Dong-A ST Co., Ltd.
• Jiangsu Hansoh Pharmaceutical
• Assembly Biosciences
• Arbutus Biopharma
• Vir Biotechnology
• Antios Therapeutics
• Ascletis Pharmaceuticals
• Shanghai HEP Pharmaceutical
• Romark Laboratories
• Qilu Pharmaceutical
• Golden Biotechnology
• Sunshine Lake Pharma
• Ascentage Pharma
• Vir Biotechnology
• GalaxoSmithKline
• Janssen Sciences
• Henlix
• Enyo Pharma
• Tasly Tianjin Biopharmaceutical
• Brii Biosciences
• Vaxine Pty Ltd
• Vaccitech limited
• Zhejiang Palo Alto Pharmaceuticals
• Suzhou Ribo Life Science
• PharmaEssentia
• Nucorion Pharmaceuticals
• Jiangsu HengRui Medicine
• Aligos Therapeutics
• Janssen Research & Development
• Enanta Pharmaceuticals
• Chong Kun Dang Pharmaceutical
• Guangzhou Lupeng Pharmaceutical

Key Products

• Tenofovir
• DA-2802
• HS-10234
• Vebicorvir
• AB-729
• VIR-2218
• ChAdOx1-HBV
• REP 2139
• ATI-2173
• BRII-835
• ASC22
• Hepalatide
• T101
• Nitazoxanide
• EYP001a
• QL-007
• HLX10
• Antroquinonol
• JNJ-7376398
• GLS4
• IONIS-HBVRx
• APG-1387
• VIR-2218
• ASC42
• PA1010
• RBD1016
• Ropeginterferon alfa 2b
• NCO-48
• HRS5091
• Cetrelimab
• EDP-514

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/h3tx8z